Trial · NCT00101660
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Imatinib-resistant Participants With Major Cytogenetic Response (MCyR) | Dasatinib, 70 mg, Twice Daily (BID) | 159 | Participants | ||
| Number of Imatinib-intolerant Participants With MCyR | Dastinib, 70 mg, BID | 81 | Participants | ||
| Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months | Dasatanib, 70 mg BID | Imatinib-intolerant group: 12 months (n=81) | 98.5 | Percentage of participants | |
| Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months | Dasatanib, 70 mg BID | Imatinib-intolerant group: 24 months (n=81) | 96.7 | Percentage of participants | |
| Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months | Dasatanib, 70 mg BID | Imatinib-resistant group: 12 months (n=159) | 93.7 | Percentage of participants | |
| Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months | Dasatanib, 70 mg BID | Imatinib-resistant group: 24 months (n=159) | 83.6 | Percentage of participants | |
| Median Time From First Dosing Date to Date of MCyR | Dasatinib, 70 mg BID | Imatinib-intolerant | 2.79 | Full Range 0.79 to 16.39 | Months |
| Median Time From First Dosing Date to Date of MCyR | Dasatinib, 70 mg BID | Imatinib-resistant | 2.92 | Full Range 0.95 to 22.37 | Months |
| Number of Participants With Complete Hematologic Response (CHR) | Dasatinib, 70 mg BID | Imatinib-intolerant (n=99) | 93 | Participants | |
| Number of Participants With Complete Hematologic Response (CHR) | Dasatinib, 70 mg BID | Imatinib-resistant (n=288) | 259 | Participants | |
| Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months | Dasatinib,70 mg BID | Imatinib-intolerant: 12 months (n=93) | 97.7 | Percentage of participants | |
| Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months | Dasatinib,70 mg BID | Imatinib-intolerant: 24 months (n=93) | 93.5 | Percentage of participants | |
| Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months | Dasatinib,70 mg BID | Imatinib-resistant: 12 months (n=259) | 90.4 | Percentage of participants | |
| Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months | Dasatinib,70 mg BID | Imatinib-resistant: 24 months (n=259) | 78.8 | Percentage of participants | |
| Median Time From First Dosing Until CHR | Dasatinib, 70 mg BID | Imatinib-intolerant (n=93) | 0.49 | Full Range 0.46 to 3.78 | Months |
| Median Time From First Dosing Until CHR | Dasatinib, 70 mg BID | Imatinib-resistant (n=259) | 0.53 | Full Range 0.46 to 12.39 | Months |
| Number of Participants With Major Molecular Response (MMR) | Dasatinib, 70 mg BID | Imatinib-intolerant (n=99) | 73 | Participants | |
| Number of Participants With Major Molecular Response (MMR) | Dasatinib, 70 mg BID | Imatinib-resistant (n=288) | 102 | Participants | |
| Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire Scores | Dasatinib,70 mg BID | Imatinib-intolerant: Total FACT-G (n=80) | 34 | Participants | |
| Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire Scores | Dasatinib,70 mg BID | Imatinib-intolerant: PWB (n=80) | 36 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00101660/results